2
Announcements
Trials
Browse
Landscape
Status
No longer available
1
Sponsor Class
INDUSTRY
1
Study Type
Expanded_access
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Polycythemia Vera
6
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
6
Carcinoma, Hepatocellular
6
Thrombocythemia, Essential
5
Neoplasms
3
Melanoma
3
Skin Neoplasms
2
Philadelphia Chromosome
2
Neoplasm Metastasis
2
Myeloproliferative Disorders
2
Leukemia
2
Hepatitis C, Chronic
2
Carcinoma, Squamous Cell
2
Brain Neoplasms
2
Solid Cancers
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pancreatic Neoplasms
1
Neoplasm, Residual
1
Neoplasm of Uncertain Malignant Potential
1
Liver Cirrhosis
1
Leukemia, Myeloid, Acute
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Influenza, Human
1
Infections
1
Hepatitis D
1
Hepatitis C
1
Hepatitis B, Chronic
1
Hepatitis B
1
Hemangiosarcoma
1
Interventions
Ultrasonography
3
Tomography, X-Ray Computed
2
Colonoscopy
2
Blood Specimen Collection
2
tremelimumab
1
peginterferon alfa-2a
1
lenvatinib
1
hepatitis C immune globulin, human
1
fluoromisonidazole
1
epigallocatechin gallate
1
durvalumab
1
babao dan
1
Weights and Measures
1
Vitamin B 6
1
Urination
1
Tomography
1
Tidal Volume
1
Tenofovir
1
Surgical Procedures, Operative
1
Standard of Care
1
Shadowing Technique, Histology
1
Rosuvastatin Calcium
1
Radiotherapy
1
Radiomics
1
Propranolol
1
Probiotics
1
Preoperative Exercise
1
Positron-Emission Tomography
1
Portasystemic Shunt, Transjugular Intrahepatic
1
Population Groups
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Liver Cirrhosis
×
peginterferon alfa-2a
×
Clear all
NCT05683548
2025-02-17
RCAP
Replicor Inc.
No longer available